Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Must Maintain Oversight Role In PMI Development, Groups Urge

This article was originally published in The Pink Sheet Daily

Executive Summary

Advocates argue patient medication information documents could resemble advertising if FDA does not review and approve them before they are used, regardless of resources concerns.

You may also be interested in...



FDA's Chicken Or Egg Question For Pharmacy Leaflets: Should Benefit Or Risk Come First?

FDA will look at which should come first – benefits or risks – when it studies patients' response to three one-page prototypes of patient medication information.

FDA's Chicken Or Egg Question For Pharmacy Leaflets: Should Benefit Or Risk Come First?

FDA will look at which should come first – benefits or risks – when it studies patients' response to three one-page prototypes of patient medication information.

Assurance Vs. Flexibility: Unit-Of-Use Packaging Offers Trade-Offs For Patient Leaflets

Manufacturers would have full responsibility for writing, producing, and ultimately delivering the new patient medication information document with their products, if FDA decides the industry should fully adopt the unit-of-use packaging.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071236

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel